Released: August 22, 2024
Expiration: August 21, 2025
Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2023.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346.
Du ZL, Wang Y, Wang DY, et al. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database. Breast Cancer Res Treat. 2020;183:429-438.
Freedman RA, Caswell-Jin JL, Hassett M, et al. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer—cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. J Clin Oncol. 2024;42:2233-2235.
Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
Giordano SH, Freedman RA, Somerfield MR, et al. Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update. J Clin Oncol. 2022;40:307-309.
Han HS, Vikas P, Costa RLB, et al. Early-stage triple-negative breast cancer journey: beginning, end, and everything in between. Am Soc Clin Oncol Educ Book. 2023 Jun:43:e390464.
Hortobagyi G, Stroyakovsky D, Yardley D, et. al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS03-03.
Jin J, Cao J, Li B, Li T, et al. Landscape of DNA damage response gene alterations in breast cancer: a comprehensive investigation. Cancer. 2023;129:845-859.
Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347.
Kalinsky K, Barlow WE, Pathak HB, et al. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2024. Abstract 505.
Li A, Geyer FC, Blecua P, et al. Homologous recombination DNA repair defects in PALB2-associated breast cancers. NPJ Breast Cancer. 2019;5:23.
Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:1956-1962.
Morice PM, Leary A, Dolladille C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8:e122-e134.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v2.2024. www.nccn.org. Accessed June 27, 2024.
Olaparib [prescribing information]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2023.
Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme; 2024.
Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33:616-627.
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
Schmid P, Cortés J, Dent RA, et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA18.
Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080-1091.
Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023:15:17588359231178125.
Sparano J, Gray RJ, Makower D, et al. Trial Assigning Individualized Options for Treatment (TAILORx): an update including 12-year event rates. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS1-05.
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111-121.
Tarantino P, Leone J, Vallejo CT, et al. Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ Breast Cancer. 2024;10:26.
Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38:4274-4282.
Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
US Food and Drug Administration. FDA expands early breast cancer indication for abemaciclib with endocrine therapy. www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy. Accessed June 27, 2024.
US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools. Accessed June 27, 2024.
Yardley DA, Untch M, Barrios CH, et al. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2024. Abstract 512.
Access to and use of this Interactive Decision Support Tool titled, “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal adjuvant therapy choices for treating individuals with HER2-negative early breast cancer who have already undergone surgery and, if applicable, are already receiving adjuvant endocrine therapy. The information provided is based on the expert guidance of Kevin Kalinsky, MD, MS; Laura A. Huppert, MD; Reshma L. Mahtani, DO; Laura M. Spring, MD; and Tiffany A. Traina, MD, FASCO.
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights, are disclaimed.
Any trademarks are the property of respective companies.
© 2024 Clinical Care Options, LLC. All rights reserved.